Windlas Biotech Ltd Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 19 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹2.0K Cr
The company does not provide specific growth guidance or fixed CAGR projections for the next 3 to 5 years. Management does not provide specific growth guidance or CAGR targets for revenues or earnings.
From Windlas Biotech Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹994
Market Cap
₹2.0K Cr
P/E Ratio
29.5
How does Windlas Biotech Ltd rank in Pharmaceuticals & Biotechnology?
Compare Windlas Biotech Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Windlas Biotech Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹238 Cr, net profit ₹16 Cr.
Full financials →📊 Revenue & Sales Performance
- →The company does not provide specific growth guidance or fixed CAGR projections for the next 3 to 5 years.
- →Commitment is towards long-term growth by leveraging every opportunity and unlocking avenues across all verticals (CDMO, Trade Generics, Exports).
- →Past performance indicates strong growth; e.g., ~50% growth over last 2 financial years.
- →Market dynamics and industry trends suggest room for continuing growth, supported by factors like:
- → - Increasing quality and compliance pressures benefiting organized players.
- → - Growth in trade generics (often undocumented in industry numbers).
- → - Investments in capacity expansion, including Plant 6 and injectables facility.
- →Management emphasizes sustained efforts, operational efficiency, and strategic capacity additions rather than promising fixed growth percentages.
- →Growth will be volume-driven primarily, with opportunities to expand product portfolios and geographic reach.
- →Competitive intensity expected but offset by increasing market acceptance and quality perception improvements.
📈 Profitability & Margins
- →Management does not provide specific growth guidance or CAGR targets for revenues or earnings.
- →Commitment is to focus on long-term value creation rather than short-term growth percentages.
- →The company aims to leverage all growth opportunities across its three verticals (CDMO, Trade Generics, Exports).
- →Growth visibility is influenced by capacity expansions (Plant 6, injectable facility) and potential inorganic opportunities.
- →Past financial performance shows consistent strong growth, e.g., around 20%+ Y-o-Y revenue growth recently.
- →Margins are expected to expand gradually as operational efficiencies improve alongside capacity ramp-up, especially in injectables.
- →The company maintains a disciplined approach towards capital deployment (capex and potential M&A) while rewarding shareholders via dividend payouts (~20% of profit).
- →Management emphasizes that growth can fluctuate and is contingent on market dynamics and execution capabilities, and is therefore cautious on firm commitments to specific growth rates.
🏗️ Capital Expenditure Plans
- →Plant 6 refurbishment and validation is ongoing, with 2-3 more quarters expected before full commercialization; CapEx planned is INR 40-50 crores.
- →After Plant 6 reaches full capacity, Windlas Biotech aims to expand into another dosage form if no inorganic opportunities arise.
- →Injectable facility expansion (Plant 5 Phase II) will be considered once peak utilization is achieved; such expansion can be done within 1-2 quarters as utilities are built-in.
- →Organic CapEx will be used judiciously alongside inorganic opportunities for strategic growth.
- →The Company is exploring M&A opportunities but has not finalized any deal yet.
- →Capital allocation focuses on strategic dosage form expansion, especially post-Plant 6 capacity utilization and injectable business stabilization.
💰 Fundraising & Capital Structure
- →No specific mention of any current or imminent fundraising through debt or equity in the document.
- →The company has been accumulating cash over a long period and currently sits on a significant cash balance.
- →They are exploring M&A opportunities but have not yet found a solid target and are not in final stages of any deal.
- →Capital expenditures (CapEx) are planned and budgeted internally (INR 40-50 crores for Plant 6), indicating use of internal cash rather than raising external funds.
- →Management emphasizes judicious and thoughtful use of capital for organic and inorganic growth but no immediate plans to raise funds externally have been indicated.
📋 Order Book & Pipeline
- →The company regards order book size and client-wise order details as competitively sensitive information.
- →Therefore, Windlas Biotech Limited has not disclosed specific figures related to current order book size or pending orders in value or volume terms.
- →Management focuses more on broad-based business development and maintaining a diversified customer base rather than highlighting individual order values.
- →There is an emphasis on sustained growth across verticals driven by volume and new client additions, but exact order backlog data is not shared publicly.
Key Metrics
Continue your research
What Windlas Biotech's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Sigachi Indust. (Q1 FY26)
INR 60 crores from Hyderabad plant in next 6 months, with some recovery from other units (Dahej, Jhagadia). Key concall takeaways from Sigachi Industries Ltd's…
- Sai Life Sciences Ltd (Q1 FY26)
Sai Life Sciences reported a strong Q1 FY'26 with revenue up 77% YoY, driven mainly by CDMO (113% growth) and CRO (38% growth). Key concall takeaways from Sai…
- Cipla Ltd (Q1 FY26)
One Africa business grew 11% YoY, with continued focus on expansion. Key concall takeaways from Cipla's Q1 FY26 earnings call — and how it ranks against sector…
- Anthem Biosciences Ltd (Q1 FY26)
Capacity utilization in custom synthesis is around 70%, with expansions ongoing, indicating potential for further revenue growth. Key concall takeaways from…
Frequently Asked Questions
What were Windlas Biotech Ltd Q1 FY26 results?
The company does not provide specific growth guidance or fixed CAGR projections for the next 3 to 5 years. Management does not provide specific growth guidance or CAGR targets for revenues or earnings.
What is Windlas Biotech Ltd share price analysis?
Windlas Biotech Ltd currently shows a neutral. The stock trades at a P/E of 29.5 with a market cap of ₹1,959 Cr. Investors should review the full earnings analysis for detailed insights.
Is Windlas Biotech Ltd planning capital expenditure?
Plant 6 refurbishment and validation is ongoing, with 2-3 more quarters expected before full commercialization; CapEx planned is INR 40-50 crores.
Keep Windlas Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.